Broad Pipeline of Internally Discovered Agents
Lead asset in pivotal trials both globally and in China, additional pivotal programs to start in 2017.
In total, over 980 patients and healthy adults2 enrolled 4 programs including combination trials
- All 4 compounds in clinic both globally and in China
- Lead compound in pivotal trials both globally and in China
1 Limited collaboration with Merck KGaA;
2As of November 7, 2016
- All 4 compounds in clinic in China
- Lead compound in pivotal trials in China
Combinations in Development
Broad internal portfolio provides advantages in combination therapy.